What does this round make possible?

The round is intended to move Rōvn from product development and acknowledged interest into signed pilots, measured starts and evidence of accepted reuse.

The proof plan makes those results inspectable: a facility-defined baseline, a complete workflow record and a finance-reviewed result.

Use-of-funds priorities are a plan. Burn, runway and supporting financial assumptions are discussed privately with qualified investors.

The financing case is strongest when the next round of spending produces evidence that changes what the company can responsibly do. Product completion alone does not answer buyer commitment, delivery effort or repeat use. Those questions need operating results alongside engineering progress.

Can the selected workflow operate?

Fund the source, security, product and recovery work required for one eligible path. The evidence is a reviewed activation scope and a source-confirmed, facility-accepted outcome.

Will an interested organization buy?

Fund founder-led scoping and commercial work. The evidence is an executed paid agreement with a clear buyer, permitted data scope and measurable result.

Does the value survive delivery cost?

Fund a complete baseline and operating review. The evidence includes finance-accepted savings, total customer effort and Rōvn’s own cost to deliver.

Can the result repeat?

Fund the configuration, support and product improvements needed for the next comparable deployment. The evidence is continued use and repeat outcomes within a sustainable effort budget.

Does the record become more useful?

Test accepted evidence reuse and continuing clinician utility. The evidence is actual acceptance and repeat use, with permissions and private facility boundaries preserved.

The plan prioritizes what is needed to earn the first eligible deployment, then the work needed to make that deployment repeatable. Security and source prerequisites can progress alongside customer scoping. A broader sales effort should follow a credible account of implementation capacity and the work needed to activate the next site.

The professional network and whole-practice vision shape the architecture, but do not require the round to fund every future product at once. Early career utility supports the workforce relationship. Larger community, intelligence and departmental packages require their own evidence before receiving a wider deployment commitment.

This public room does not invent allocation percentages, burn or months of runway. Those numbers require the current cash position, hiring assumptions, vendor costs, pilot cash timing and contingency plan. They should be reconciled in financing diligence rather than reverse-engineered from a round headline.

The near-term bet is that the team can turn documented institutional interest and a designed product into paid, accepted workforce operations. The next bet is that ongoing utility supports recurring facility revenue and a continuing clinician relationship. The larger bet is that permissioned operating history improves subsequent work and enables connected products.

Those bets have different evidence requirements. A signed pilot improves the commercial case. A successful workflow improves the delivery case. Paid continuation and lower repeat-deployment effort improve the economic case. A second facility accepting eligible evidence improves the portability case. None should stand in for all the others.

The dated goals give these questions a near-term shape. They are management targets, not conditions already achieved or a promise of a future financing valuation. The team should report what happened, the relevant denominator and the next decision when the evidence changes.

Financing review should reconcile the proposed SAFE terms with the definitive documents, current capitalization and any existing financing obligations. The operating plan should show expected deployment costs, staffing assumptions, timing of customer cash and a downside if pilots or activation take longer.

The same review should distinguish uses of capital that enable the first outcome from optional expansion. Where a supporting record or assumption needs confirmation, it remains an open diligence item. The public target terms are the founder-confirmed October 1 plan; they do not establish commitments from investors or an executed financing.